Matinas BioPharma Holdings (MTNB) Other Operating Expenses (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Other Operating Expenses of -$73000.0 for Q4 2025, down 101.65% year-over-year from $4.4 million in Q4 2024, and down 166.36% quarter-over-quarter from $110000.0 in Q2 2025.
Matinas BioPharma Holdings (MTNB) Other Operating Expenses (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Other Operating Expenses for 8 consecutive years, with -$73000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Operating Expenses fell 101.65% year-over-year to -$73000.0; the TTM figure through Mar 2026 stood at $37000.0 (down 99.16% YoY), while the FY2025 annual figure was $37000.0, down 99.16% from the prior year.
- Other Operating Expenses declined to -$73000.0 in Q4 2025 per MTNB's latest filing, from $110000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $4.4 million in Q4 2024 and bottomed at -$73000.0 in Q4 2025.
- Historically, Other Operating Expenses has averaged $625142.9 across 3 years, with a median of -$20000.0 in 2021.
- Annual changes were most pronounced in 2021 — Other Operating Expenses soared 75.0% — and 2025, when it tumbled 101.65%.
- Matinas BioPharma Holdings' Other Operating Expenses stood at -$15000.0 in 2021, then surged by 29640.0% to $4.4 million in 2024, then tumbled by 101.65% to -$73000.0 in 2025.
- Business Quant data shows MTNB's Other Operating Expenses at -$73000.0 in Q4 2025, $110000.0 in Q2 2025, and $4.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -138,000.00 |
| Dec 31, 2025 | -73,000.00 |
| Jun 30, 2025 | 110,000.00 |
| Dec 31, 2024 | 4.43 Mn |
| Dec 31, 2021 | -15,000.00 |
| Sep 30, 2021 | -29,000.00 |
| Jun 30, 2021 | -28,000.00 |
| Mar 31, 2021 | -20,000.00 |
| Dec 31, 2020 | -29,000.00 |
| Sep 30, 2020 | -90,000.00 |
| Jun 30, 2020 | -93,000.00 |
| Mar 31, 2020 | -80,000.00 |
| Dec 31, 2019 | -122,600.00 |
| Sep 30, 2019 | -62,100.00 |
| Jun 30, 2019 | -58,700.00 |
| Mar 31, 2019 | -116,700.00 |
| Sep 30, 2018 | -274,000.00 |
| Jun 30, 2018 | -341,828.00 |
| Mar 31, 2018 | -172.00 |
| Jun 30, 2014 | -5,385.00 |